BE2012C040I2 - - Google Patents

Info

Publication number
BE2012C040I2
BE2012C040I2 BE2012C040C BE2012C040C BE2012C040I2 BE 2012C040 I2 BE2012C040 I2 BE 2012C040I2 BE 2012C040 C BE2012C040 C BE 2012C040C BE 2012C040 C BE2012C040 C BE 2012C040C BE 2012C040 I2 BE2012C040 I2 BE 2012C040I2
Authority
BE
Belgium
Prior art keywords
administering
therapy
prevention
patient
rapid
Prior art date
Application number
BE2012C040C
Other languages
English (en)
French (fr)
Original Assignee
Apbi Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22542905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2012C040(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Apbi Holdings Llc filed Critical Apbi Holdings Llc
Publication of BE2012C040I2 publication Critical patent/BE2012C040I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
BE2012C040C 1999-09-03 2012-10-11 BE2012C040I2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15243599P 1999-09-03 1999-09-03
EP00957264A EP1225881B1 (en) 1999-09-03 2000-08-22 The use of dapoxetine, a rapid-onset selective serotonin reuptake inhibitor, for treating sexual dysfunction
PCT/US2000/020788 WO2001017521A1 (en) 1999-09-03 2000-08-22 Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction

Publications (1)

Publication Number Publication Date
BE2012C040I2 true BE2012C040I2 (uk) 2019-10-16

Family

ID=22542905

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2012C040C BE2012C040I2 (uk) 1999-09-03 2012-10-11

Country Status (34)

Country Link
US (4) US7718705B1 (uk)
EP (3) EP1225881B1 (uk)
JP (1) JP3194734B2 (uk)
KR (1) KR100719977B1 (uk)
CN (1) CN1222283C (uk)
AT (1) ATE318135T1 (uk)
AU (1) AU762934B2 (uk)
BE (1) BE2012C040I2 (uk)
BG (1) BG65677B1 (uk)
BR (1) BR0014166A (uk)
CA (1) CA2383785C (uk)
CY (1) CY2012028I1 (uk)
CZ (1) CZ299712B6 (uk)
DE (2) DE122009000036I2 (uk)
DK (1) DK1225881T3 (uk)
EA (1) EA004101B1 (uk)
EE (1) EE05315B1 (uk)
ES (2) ES2393582T3 (uk)
FR (1) FR12C0052I2 (uk)
HK (2) HK1047545B (uk)
HR (1) HRP20020189A2 (uk)
HU (1) HU229150B1 (uk)
IL (2) IL148159A0 (uk)
LU (1) LU92204I2 (uk)
MX (1) MXPA02001811A (uk)
MY (1) MY125490A (uk)
NO (2) NO330562B1 (uk)
NZ (1) NZ517038A (uk)
PL (1) PL211402B1 (uk)
SI (1) SI1225881T1 (uk)
TW (3) TW200524582A (uk)
UA (1) UA75580C2 (uk)
WO (1) WO2001017521A1 (uk)
ZA (1) ZA200201407B (uk)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
ES2393582T3 (es) * 1999-09-03 2012-12-26 Apbi Holdings, Llc Procedimiento de utilización de inhibidores de la recaptación de serotonina selectivos de inicio rápido de acción para el tratamiento de las disfunciones sexuales
US6974839B2 (en) 2001-03-16 2005-12-13 Dmi Biosciences, Inc. Method of delaying ejaculation
CZ20032644A3 (en) 2001-03-29 2004-06-16 Bristol-Myers Squibb Company Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
CA2410966C (en) * 2002-11-01 2005-11-22 Craig J. Hudson Sexual desire and performance enhancement with protein-bound tryptophan
AU2003903597A0 (en) * 2003-07-11 2003-07-24 Jakov Vaisman Treatment of premature ejaculation
GB0318706D0 (en) * 2003-08-08 2003-09-10 Pfizer Ltd Selective serotonin reuptake inhibitors in the treatment of disease
DE102009015702A1 (de) 2009-03-31 2010-10-07 Ratiopharm Gmbh Tabletten enthaltend Dapoxetin und Trockenverarbeitungsverfahren zu deren Herstellung
DE102009058321A1 (de) 2009-12-15 2011-06-16 Ratiopharm Gmbh Schmelztablette, enthaltend Dapoxetin
EP2591773A4 (en) 2010-07-06 2014-11-26 Navipharm Co Ltd TEMPORARY RELEASED PHARMACEUTICAL COMPOSITION WITH DAPOXIN FOR ORAL ADMINISTRATION
RU2463033C2 (ru) * 2010-08-06 2012-10-10 Василий Федорович Пятин Способ лечения преждевременной эякуляции
CN103100085A (zh) * 2011-11-09 2013-05-15 上海兰蒂斯生物医药科技有限公司 一种药物组合物
CN103130660B (zh) * 2011-11-25 2014-09-17 厦门福满药业有限公司 一类达泊西汀的酸式盐及其晶体,以及晶体的制备方法
WO2014042416A1 (ko) * 2012-09-13 2014-03-20 주식회사 씨티씨바이오 다폭세틴 유리염기를 함유하는 경구용 조성물
KR101432905B1 (ko) 2012-12-11 2014-08-21 가톨릭대학교 산학협력단 다폭세틴을 유효성분으로 포함하는 유전적 통증 치료용 약학 조성물
US20160101093A1 (en) * 2013-05-21 2016-04-14 Jason B. Wynberg Methods for the treatment of premature ejaculation
CN103735525B (zh) * 2014-02-12 2015-05-06 江苏仁寿药业有限公司 一种达泊西汀片剂及制备方法
US20160045454A1 (en) * 2014-08-12 2016-02-18 Tianxin Wang Therapeutical methods, formulations and nutraceutical formulations
US20180071269A1 (en) 2015-08-12 2018-03-15 Tianxin Wang Therapeutical methods, formulations and nutraceutical formulations
WO2018102233A1 (en) * 2016-11-30 2018-06-07 Wang tian xin Therapeutical methods, formulations and nutraceutical formulations
TR201620151A2 (en) 2016-12-30 2018-07-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING TADALAFIL AND DAPOXETIN
CN113143879A (zh) * 2021-05-07 2021-07-23 苏州康恒研新药物技术有限公司 一种盐酸达泊西汀缓释片的制备方法
CN113181127A (zh) * 2021-05-07 2021-07-30 苏州康恒研新药物技术有限公司 一种盐酸达泊西汀微丸片的制备方法
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4194009A (en) * 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
US4018895A (en) * 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4207343A (en) * 1978-06-22 1980-06-10 Eli Lilly And Company 1-Phenyl-3-(substituted phenoxy)propylamines
US4329356A (en) * 1980-10-31 1982-05-11 Eli Lilly And Company Treatment of hypertension with fluoxetine and l-5-hydroxytryptophane
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5135947A (en) * 1987-04-09 1992-08-04 Eli Lilly And Company 1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors
US4866046A (en) 1988-05-31 1989-09-12 Top Laboratories, Inc. Low-dosage sublingual aspirin
US5082667A (en) 1988-06-07 1992-01-21 Abbott Laboratories Solid pharmaceutical dosage in tablet triturate form and method of producing same
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US4940731A (en) 1989-08-30 1990-07-10 Pfizer Inc. Method of treating premature ejaculation using sertraline
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5589511A (en) 1990-08-13 1996-12-31 Sepracor Inc. Method for treating migraine headaches using optically pure S(+) fluoxetine
US5151448A (en) * 1991-07-12 1992-09-29 Crenshaw Roger T Method for treating premature ejaculation
US5151488A (en) * 1991-11-12 1992-09-29 The Mead Corporation Liquid crystal polymers containing a repeating bisoxazole structure
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5248699A (en) 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5292962A (en) 1992-12-11 1994-03-08 Eli Lilly And Company Intermediates to 1-phenyl-3-naphthalenyloxy-propanamines
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
ZA93694B (en) * 1993-02-01 1993-06-03 Lilly Co Eli Pharmaceutical treatments.
US5276042A (en) 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
IT1264965B1 (it) 1993-11-12 1996-10-17 Giorgio Cavallini Uso di alfa 1-bloccanti nel trattamento della eiaculazione precoce
PT758895E (pt) 1994-04-22 2000-05-31 Univ Kingston Formas de dosagem sublingual contendo apomorfina para uso no tratamento da disfuncao erectil
CA2134038C (en) 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5457121A (en) 1994-09-02 1995-10-10 Eli Lilly And Company Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake
US5597826A (en) 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
ZA958725B (en) 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
EP0714663A3 (en) 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5627196A (en) 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5789402A (en) 1995-01-17 1998-08-04 Eli Lilly Company Compounds having effects on serotonin-related systems
US5614523A (en) 1995-01-17 1997-03-25 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5576321A (en) 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
AU4918796A (en) 1995-02-10 1996-08-27 Eli Lilly And Company Methods of treating or preventing psychiatric disorders
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
DE69637097T2 (de) 1995-10-13 2007-09-20 Neurosearch A/S 8-Azabicyclo(3.2.1)Oct-2-en-Derivate, deren Herstellung und Anwendung
US5758911A (en) * 1996-02-07 1998-06-02 Northrop Grumman Corporation Linear motion wind driven power plant
US5897864A (en) 1996-05-23 1999-04-27 Cohen; Alan J. Method for treating sexual dysfunction disorders with compositions containing ginkgo biloba
US5846982A (en) 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
US5912256A (en) 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5830500A (en) * 1996-07-22 1998-11-03 Pentech Pharmaceuticals, Inc. Low dose fluoxetine tablet
US5672612A (en) 1996-09-09 1997-09-30 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US5910319A (en) 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
NZ501249A (en) 1997-07-01 2001-06-29 Pfizer Prod Inc Delayed-release (pH or enzymatically triggered) dosage forms of sertraline
EP0999830A1 (en) 1997-07-01 2000-05-17 Pfizer Inc. Sertraline salts and sustained-release dosage forms of sertraline
AU724635B2 (en) 1997-07-01 2000-09-28 Pfizer Products Inc. Gelatine encapsulated solution dosage forms of sertraline
FR2765483B1 (fr) * 1997-07-04 2000-02-04 Philippe Gorny Medicament destine a traiter les dysfonctions erectiles
US6228864B1 (en) 1997-10-28 2001-05-08 Vivus, Inc. Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation
US6037360A (en) 1997-10-28 2000-03-14 Vivus, Incorporated Administration of 5-HT3 receptor antagonists to treat premature ejaculation
US5922341A (en) 1997-10-28 1999-07-13 Vivus, Incorporated Local administration of pharmacologically active agents to treat premature ejaculation
UA66370C2 (en) * 1997-12-16 2004-05-17 Lilly Co Eli Arylpiperazines having activity to setotonin 1 receptors
PA8469101A1 (es) 1998-04-09 2000-09-29 Pfizer Prod Inc Ligandos azabiciclicos de receptores 5ht1
US6303627B1 (en) 1998-06-19 2001-10-16 Eli Lilly And Company Inhibitors of serotonin reuptake
CA2335336A1 (en) 1998-06-19 1999-12-23 James Edmund Audia Inhibition of serotonin reuptake
FR2781671A1 (fr) 1998-07-28 2000-02-04 Synthelabo Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique
US6150376A (en) 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
CA2346335C (en) 1998-10-13 2006-04-18 Pfizer Products Inc. Sertraline oral concentrate
WO2000067729A1 (en) * 1999-05-06 2000-11-16 Pentech Pharmaceuticals, Inc. Regimen and kit for amelioration of premature ejaculation
US20010003120A1 (en) * 1999-05-14 2001-06-07 M. D. Robert Hines Method for treating erectile dysfunction
ES2393582T3 (es) * 1999-09-03 2012-12-26 Apbi Holdings, Llc Procedimiento de utilización de inhibidores de la recaptación de serotonina selectivos de inicio rápido de acción para el tratamiento de las disfunciones sexuales

Also Published As

Publication number Publication date
BG106461A (en) 2002-12-29
BG65677B1 (bg) 2009-06-30
TW200524582A (en) 2005-08-01
TW201018459A (en) 2010-05-16
HUP0202687A2 (hu) 2002-12-28
IL148159A0 (en) 2002-09-12
EE200200107A (et) 2003-04-15
CN1222283C (zh) 2005-10-12
DE60026146D1 (de) 2006-04-27
HRP20020189A2 (en) 2004-02-29
CY2012028I2 (el) 2017-04-05
NO330562B1 (no) 2011-05-16
ES2256032T3 (es) 2006-07-16
FR12C0052I2 (fr) 2013-08-16
CZ299712B6 (cs) 2008-10-29
HUP0202687A3 (en) 2006-03-28
DE122009000036I1 (de) 2009-11-05
NO2012015I1 (no) 2012-09-11
MY125490A (en) 2006-08-30
LU92204I2 (fr) 2013-07-23
HK1047545B (zh) 2006-09-22
FR12C0052I1 (uk) 2012-05-10
US7718705B1 (en) 2010-05-18
NO20021035L (no) 2002-05-02
JP3194734B2 (ja) 2001-08-06
KR100719977B1 (ko) 2007-05-21
US20050261377A1 (en) 2005-11-24
DE122009000036I2 (de) 2010-05-06
MXPA02001811A (es) 2002-08-06
EP1889614A2 (en) 2008-02-20
NO20021035D0 (no) 2002-03-01
BR0014166A (pt) 2002-05-14
WO2001017521A1 (en) 2001-03-15
EA004101B1 (ru) 2003-12-25
AU6891100A (en) 2001-04-10
CY2012028I1 (el) 2017-04-05
EP1671628B1 (en) 2012-10-03
US20050215617A1 (en) 2005-09-29
HU229150B1 (hu) 2013-09-30
EP1225881A1 (en) 2002-07-31
SI1225881T1 (sl) 2006-06-30
AU762934B2 (en) 2003-07-10
IL148159A (en) 2009-11-18
HK1091418A1 (en) 2007-01-19
PL364924A1 (en) 2004-12-27
NZ517038A (en) 2003-04-29
ZA200201407B (en) 2003-07-30
CA2383785C (en) 2009-02-17
CN1387432A (zh) 2002-12-25
EP1225881B1 (en) 2006-02-22
DK1225881T3 (da) 2006-06-12
UA75580C2 (uk) 2006-05-15
NO2012015I2 (no) 2013-08-26
ES2393582T3 (es) 2012-12-26
EP1671628A1 (en) 2006-06-21
HK1047545A1 (en) 2003-02-28
JP2001089394A (ja) 2001-04-03
US20140221497A1 (en) 2014-08-07
CA2383785A1 (en) 2001-03-15
KR20020025252A (ko) 2002-04-03
EE05315B1 (et) 2010-08-16
CZ2002784A3 (cs) 2002-09-11
DE60026146T2 (de) 2006-08-17
EP1889614A3 (en) 2010-09-22
PL211402B1 (pl) 2012-05-31
EA200200324A1 (ru) 2002-08-29
ATE318135T1 (de) 2006-03-15
TWI312678B (en) 2009-08-01
TWI367751B (en) 2012-07-11

Similar Documents

Publication Publication Date Title
BE2012C040I2 (uk)
IL151164A0 (en) Azacyclic compounds for use in the treatment of serotonin related diseases
BR0316753A (pt) Método de tratamento para disfunção sexual
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
IL153733A0 (en) A new use for deferiprone
MXPA03004288A (es) Tratamiento de disfuncion sexual inducida por farmaco antidepresivo con apomorfina.
WO1999065475A3 (en) Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
PT1183046E (pt) Derivado de aminotetralina para a terapia de doencas cardiovasculares
CY1118068T1 (el) Η χρηση δαποξετινης, ενος ταχειας-εναρξης επιλεκτικου αναστολεα εκ νεου αναληψης σepοτονινης για την θepαπευτικη αντιμετωπιση σεξουαλικης δυσλειτουργιας
UA33498A (uk) Спосіб лікування терапевтично резистентних форм шизофренії